Compounds > 1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine
Page last updated: 2024-09-03

1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine and sertraline hydrochloride

1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine has been researched along with sertraline hydrochloride in 1 studies

Compound Research Comparison

Studies
(1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine)		Trials
(1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine)		Recent Studies (post-2010)
(1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine)		Studies
(sertraline hydrochloride)		Trials
(sertraline hydrochloride)		Recent Studies (post-2010) (sertraline hydrochloride)
5301523013

Protein Interaction Comparison

ProteinTaxonomy1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine (IC50)sertraline hydrochloride (IC50)
DRattus norvegicus (Norway rat)0.07
D(3) dopamine receptorRattus norvegicus (Norway rat)0.07
D(1B) dopamine receptorRattus norvegicus (Norway rat)0.07
D(4) dopamine receptorRattus norvegicus (Norway rat)0.07
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)0.07
D(2) dopamine receptorRattus norvegicus (Norway rat)0.07
TransporterRattus norvegicus (Norway rat)0.07

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J1

Other Studies

1 other study(ies) available for 1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine and sertraline hydrochloride

ArticleYear
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
    Nature chemical biology, 2009, Volume: 5, Issue:10

    Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection

2009